Powered by OpenAIRE graph
Found an issue? Give us feedback

IBEC

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
Country: Spain
110 Projects, page 1 of 22
  • Funder: European Commission Project Code: 278557
    more_vert
  • Funder: European Commission Project Code: 101130395
    Overall Budget: 2,202,330 EURFunder Contribution: 2,202,330 EUR

    Sustainability is one of the most important concepts nowadays, being able to drive activities in several sectors, namely environment preservation, society, and economy. In Analytical Chemistry, the development of sustainable devices was boosted by the introduction of microfluidic paper-based analytical devices (μPADs) whose advantages, however, are not only confined to the concept of sustainability. Indeed, paper as a functional material, confers unprecedented features to μPADs. However, paper-based devices remain exploited as only analytical tools, but have not (yet) been adopted by the Organ-on-Chip (OoC) world. The objective of the present project proposal is to alter this scenario. PHOENIX-OoC, we will radically change the OoC field by making use of paper’s versatile properties, and develop OoC devices using paper in origami configuration used (i) for cell co-cultures with the aim to better simulate different organ tissues, (ii) for (bio)sensors integration with the aim of on site/continuous monitoring of cells status/response to stimuli, and (iii) with the ultimate goal of performing accurate pharmacological studies. The main new idea is the introduction of a technology which can deliver a versatile set of electrochemical devices with new functionalities, in which, it will be possible to create ready-to-use cell culture models for drug screenings, in a custom-made manner. Because, OoC is a complex system with respect to μPADs, partners with different and needed skills have been gathered among the most important European scientists/entities in the field required. PHOENIX-OoC consortium brings together 6 partners, 4 Universities, 1 research organization, and 1 industrial partner (1 SME), 5 from 4 EU (associated)countries (Italy, Sweden, Spain, Serbia), and 1 non-EU member: Switzerland, which are renowned experts in the world on paper-based biosensors, in vitro/vivo studies, modelling, microfluidics, biomaterials, and joint tissue engineering.

    more_vert
  • Funder: European Commission Project Code: 795224
    Overall Budget: 170,122 EURFunder Contribution: 170,122 EUR

    The co-evolution between hosts and their parasites is one of the most fascinating examples of evolutionary adaptation. However, there is a paucity of information on how the human immune system co-adapts to the parasites phenotypic plasticity, and how it dynamically rearranges its molecular phenotypes aiming to counteract the pathogenic threats. Hence, many therapies for the treatment of intracellular bacteria-related infection (e.g., tuberculosis) are currently obsolete, especially because of the rise in drug resistance. In this framework, the main goal of my proposal is to decipher the unexplored phenotype ‘bar-codes’ of host-pathogen interaction, in order to reversely engineer a drug delivery platform aiming to target infected cells only, and to eradicate intracellular parasites. The final aim will be that of eradicating the severe intracellular pathogens Mycobacterium tuberculosis (Mtb), as it is the major cause of mortality related to bacterial infection worldwide. According to the World Health Organisation, in fact, approximately one-third of the world’s population is asymptomatically affected by TB, with about 9 million new cases of per year (of which 11% are children under 15 years), and 1.4 million of deaths. Despite decades of control programs, TB is still second only to HIV as the greatest killer worldwide due to a single infectious agent (the average killing rate of TB is 3 people per minute). This project will thus explore the molecular bases of Mtb-host interaction. These investigations will be used to engineer 'super-selective' polymeric nanoparticles targeting infected cells only (thus avoiding side effects), and to eradicate intracellular parasite. This will be done while adopting strategies that counteract the development drug resistance. Hence, this project will avoid falling in what has been called as the potential new ‘Dark Middle Age” era of lack of antibiotics.

    more_vert
  • Funder: European Commission Project Code: 101169266
    Funder Contribution: 3,693,330 EUR

    Rare diseases, though individually infrequent, collectively pose important challenges for patients, clinicians and researchers in terms of diagnostics, healthcare and treatment. Myotonic Dystrophy (DM), the most predominant inherited muscular dystrophy in adults, impacts 60,000-70,000 individuals in Europe. Its complex genetic and clinical variability result in a lack of robust genotype-phenotype correlations, which complicates the understanding of tissue-specific disease mechanisms, the development of effective therapies and the stratification of patients into well-defined clinical groups for clinical trial purposes. In recent years, Antisense Oligonucleotides (ASO) have emerged as promising therapeutics, notably in neuromuscular disorders. However, previous clinical trials in DM have failed due the reduced efficacy and bioavailability of the ASO tested. ENTRY-DM aims to train 14 DCs in translational research, through the combination of basic and clinical competencies across multiple disciplines, as well as strong soft and transferable skills. Our interdisciplinary network seeks to enhance scientific and technological knowledge, spanning from disease mechanisms, ASO design and delivery strategies, to clinical trial preparedness, using innovative multidisciplinary approaches and best practices. The consortium includes experts in DM research, bioengineering of model systems for preclinical drug screening, ASO chemistry, as well as clinical and neuropsychological assessment. Close collaborations with multi-sectoral partners will address the challenges in technology transfer, providing high-quality bench-to-bedside training to the next generation of researchers. Through these efforts, ENTRY-DM will catalyze ASO therapeutic development towards upcoming impeding clinical trials, establishing solid foundations for future clinical applications, increased investment and entrepreneurship ventures in the field of DM and other related diseases.

    more_vert
  • Funder: European Commission Project Code: 214402
    more_vert
  • chevron_left
  • 1
  • 2
  • 3
  • 4
  • 5
  • chevron_right

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

Content report
No reports available
Funder report
No option selected
arrow_drop_down

Do you wish to download a CSV file? Note that this process may take a while.

There was an error in csv downloading. Please try again later.